PUBLISHER: Grand View Research | PRODUCT CODE: 1301044
PUBLISHER: Grand View Research | PRODUCT CODE: 1301044
The Latin America clinical laboratory services market size is expected to reach USD 17.59 billion by 2030, expanding at a CAGR of 3.6% from 2023 to 2030, according to a new report by Grand View Research, Inc. Increase in disease prevalence and high demand for early disease diagnosis are expected to boost the market in the coming years. These factors have prompted market players to introduce innovative services to address the growing demand.
The introduction of accurate and technologically advanced products, such as biochips, microarrays, and companion diagnostics has increased the demand for early disease detection. This is mainly due to a rising healthcare expenditure owing to an increasing prevalence of chronic diseases. For instance, biochips are used for preparing thousands of DNA, RNA, or protein samples, which can be processed at the same time on a single chip. Products such as companion diagnostics also reduce the overall healthcare cost by helping physicians identify the most suitable treatment option based on the genetic makeup of a patient.
The entry of novel technologies such as automated instruments, high throughput analyzers, and multiplex diagnostic cassettes has improved the diagnostic capacity of laboratories such as Diagnosticos da America SA (DASA) to over 10 million tests a day. Moreover, in July 2022, Beckman Coulter, Inc. announced medical advancements in laboratory solutions at the 2022 AACC Clinical Lab Expo, which helps in enhancing productivity, streamlining workflows, and bringing automation to labs of all sizes.
There has been an increase in the number of hospitals providing laboratory services and facilities providing standalone services. Key players are actively involved in strategic alliances and mergers & acquisitions to enhance their market presence, leading to strong competitive rivalry. The market is price-sensitive, and therefore, players can be increasingly competitive when it comes to manufacturing cost-effective & efficient products. However, owing to the COVID-19 pandemic, the need to manage COVID-19 has increased regulatory approvals of tests, which is expected to create lucrative opportunities..